{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:55:42Z","timestamp":1793314542962,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neoadjuvant immunotherapies (NITs) have demonstrated clinical benefit in head and neck carcinoma and other cancers by enhancing T cell-mediated anti-tumor immunity. However, disease recurrence remains a major challenge in a significant proportion of patients. Characterization of T cell dynamics underlying NIT outcomes may lead to improved treatment strategies. Here, we identify baseline intratumoral T cell differentiation efficiency as a predictor of response to NIT. Clonal analysis of tumor-emergent T cells post-treatment revealed granzyme K (\n                    <jats:italic>GZMK)<\/jats:italic>\n                    expression within differentiated subsets as a marker of recent differentiation. Efficient pre-treatment differentiation of\n                    <jats:italic>GZMK<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    progenitor T cells toward activated effectors predicts increased treatment-induced tumor regression. Consistently, pre-treatment tumor-infiltrating T cell clones predominantly adopt either exhausted, tissue-resident memory-like, or peripherally enriched\n                    <jats:italic>GZMK<\/jats:italic>\n                    <jats:sup>+<\/jats:sup>\n                    progenitor states, implicating impaired intratumoral differentiation in limited anti-tumor immunity at baseline. Together, our findings demonstrate that\n                    <jats:italic>GZMK<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>+<\/jats:italic>\n                    <\/jats:sup>\n                    T cell profiles reflect baseline anti-tumor immunocompetence and offer a clinically actionable biomarker for predicting immunotherapy response. NCT04247282, ClinicalTrails.gov, registered 1\/30\/2020 and NCT03429036, ClinicalTrails.gov, registered 11\/06\/2020.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01437-7","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T21:25:21Z","timestamp":1776547521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Cem M.","family":"Sievers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Gen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Craveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Silvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Soon-Shiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Lassoued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Mydlarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy P.","family":"Judd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint T.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1158\/1078-0432.CCR-19-3977","volume":"26","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto, R. et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8(+) tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin. Cancer Res. 26, 3211\u20133219 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1437_CR2","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld, J. D. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 6, 1563\u20131570 (2020).","journal-title":"JAMA Oncol."},{"key":"1437_CR3","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin. Cancer Res. 26, 5140\u20135152 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1437_CR4","doi-asserted-by":"publisher","unstructured":"Redman, J. M. et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-beta blockade in HPV-unrelated head and neck cancer. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI161400 (2022).","DOI":"10.1172\/JCI161400"},{"key":"1437_CR5","doi-asserted-by":"crossref","unstructured":"Uppaluri, R. et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N. Engl. J. Med. 393, 37\u201350 (2025).","DOI":"10.1056\/NEJMoa2415434"},{"key":"1437_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper, T. M. et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin. Cancer Res. 28, 1345\u20131352 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1437_CR7","doi-asserted-by":"publisher","unstructured":"Li, H. et al. Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2025.02.026 (2025).","DOI":"10.1016\/j.ccell.2025.02.026"},{"key":"1437_CR8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8(+) T cells in the cancer-immunity cycle. Immunity 56, 2231\u20132253 (2023).","journal-title":"Immunity"},{"key":"1437_CR9","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"1437_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"1437_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"1437_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma. Nature 605, 532\u2013538 (2022).","journal-title":"Nature"},{"key":"1437_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1437_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ccell.2023.03.014","volume":"41","author":"C Sievers","year":"2023","unstructured":"Sievers, C. et al. Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. Cancer Cell 41, 887\u2013902.e885 (2023).","journal-title":"Cancer Cell"},{"key":"1437_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"R Yossef","year":"2023","unstructured":"Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8(+) T cells in patients with metastatic cancers. Cancer Cell 41, 2154\u20132165.e2155 (2023).","journal-title":"Cancer Cell"},{"key":"1437_CR16","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918\u20132935.e2929 (2022).","journal-title":"Cell"},{"key":"1437_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf4968","volume":"8","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. et al. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci. Immunol. 8, eadf4968 (2023).","journal-title":"Sci. Immunol."},{"key":"1437_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e1020 (2018).","journal-title":"Cell"},{"key":"1437_CR19","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"1437_CR20","doi-asserted-by":"publisher","unstructured":"Redman, J. M. et al. Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyaf006 (2025).","DOI":"10.1093\/oncolo\/oyaf006"},{"key":"1437_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1437_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1348-0421.2006.tb03876.x","volume":"50","author":"S Nagafuchi","year":"2006","unstructured":"Nagafuchi, S. et al. Autoimmune regulator (AIRE) gene is expressed in human activated CD4+ T-cells and regulated by mitogen-activated protein kinase pathway. Microbiol. Immunol. 50, 979\u2013987 (2006).","journal-title":"Microbiol. Immunol."},{"key":"1437_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41577-023-00906-5","volume":"24","author":"J Abramson","year":"2024","unstructured":"Abramson, J., Dobes, J., Lyu, M. & Sonnenberg, G. F. The emerging family of RORgammat(+) antigen-presenting cells. Nat. Rev. Immunol. 24, 64\u201377 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1437_CR24","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1084\/jem.20190249","volume":"216","author":"J Clarke","year":"2019","unstructured":"Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med. 216, 2128\u20132149 (2019).","journal-title":"J. Exp. Med."},{"key":"1437_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","volume":"40","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell 40, 410\u2013423.e417 (2022).","journal-title":"Cancer Cell"},{"key":"1437_CR26","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Invest."},{"key":"1437_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","volume":"613","author":"NL de Vries","year":"2023","unstructured":"de Vries, N. L. et al. \u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743\u2013750 (2023).","journal-title":"Nature"},{"key":"1437_CR28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4049\/immunohorizons.2100017","volume":"5","author":"S Park","year":"2021","unstructured":"Park, S., Anderson, N. L., Canaria, D. A. & Olson, M. R. Granzyme-producing CD4 T cells in cancer and autoimmune disease. Immunohorizons 5, 909\u2013917 (2021).","journal-title":"Immunohorizons"},{"key":"1437_CR29","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.immuni.2023.10.013","volume":"56","author":"M Terekhova","year":"2023","unstructured":"Terekhova, M. et al. Single-cell atlas of healthy human blood unveils age-related loss of NKG2C(+)GZMB(-)CD8(+) memory T cells and accumulation of type 2 memory T cells. Immunity 56, 2836\u20132854.e2839 (2023).","journal-title":"Immunity"},{"key":"1437_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110520","volume":"27","author":"M Fay","year":"2024","unstructured":"Fay, M. et al. TGF-beta neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice. iScience 27, 110520 (2024).","journal-title":"iScience"},{"key":"1437_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106570","volume":"146","author":"MA Rainey","year":"2023","unstructured":"Rainey, M. A., Allen, C. T. & Craveiro, M. Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: Implications for systemic anti-tumor immunity. Oral. Oncol. 146, 106570 (2023).","journal-title":"Oral. Oncol."},{"key":"1437_CR32","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.immuni.2023.06.025","volume":"56","author":"AJ Zwijnenburg","year":"2023","unstructured":"Zwijnenburg, A. J. et al. Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. Immunity 56, 1955\u20131974.e1910 (2023).","journal-title":"Immunity"},{"key":"1437_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","volume":"21","author":"G Galletti","year":"2020","unstructured":"Galletti, G. et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat. Immunol. 21, 1552\u20131562 (2020).","journal-title":"Nat. Immunol."},{"key":"1437_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","volume":"174","author":"JP Foy","year":"2022","unstructured":"Foy, J. P. et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur. J. Cancer 174, 287\u2013298 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1437_CR35","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","volume":"77","author":"A Prat","year":"2017","unstructured":"Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540\u20133550 (2017).","journal-title":"Cancer Res"},{"key":"1437_CR36","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1158\/2159-8290.CD-22-0851","volume":"13","author":"AM van der Leun","year":"2023","unstructured":"van der Leun, A. M. et al. Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T-cell and activated Treg compartment. Cancer Discov. 13, 2212\u20132227 (2023).","journal-title":"Cancer Discov."},{"key":"1437_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255.e236 (2019).","journal-title":"Cancer Cell"},{"key":"1437_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung, H. et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat. Commun. 10, 4278 (2019).","journal-title":"Nat. Commun."},{"key":"1437_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu, C. L. et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer 10, 346\u2013359 (2021).","journal-title":"Liver Cancer"},{"key":"1437_CR40","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24, 1449\u20131458 (2018).","journal-title":"Nat. Med."},{"key":"1437_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1437_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"1437_CR43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684 (2007).","journal-title":"Immunity"},{"key":"1437_CR44","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1437_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1437_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"1437_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"1437_CR48","doi-asserted-by":"publisher","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell https:\/\/doi.org\/10.1016\/j.cell.2025.03.018 (2025).","DOI":"10.1016\/j.cell.2025.03.018"},{"key":"1437_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo, X. et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell 43, 248\u2013268.e249 (2025).","journal-title":"Cancer Cell"},{"key":"1437_CR50","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1437_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch, J. S. et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat. Med. 30, 218\u2013228 (2024).","journal-title":"Nat. Med."},{"key":"1437_CR52","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res. 26, 2838\u20132848 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1437_CR53","doi-asserted-by":"publisher","unstructured":"Donado, C. A. et al. Granzyme K activates the entire complement cascade. Nature https:\/\/doi.org\/10.1038\/s41586-025-08713-9 (2025).","DOI":"10.1038\/s41586-025-08713-9"},{"key":"1437_CR54","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41586-024-08395-9","volume":"638","author":"F Lan","year":"2025","unstructured":"Lan, F. et al. GZMK-expressing CD8(+) T cells promote recurrent airway inflammatory diseases. Nature 638, 490\u2013498 (2025).","journal-title":"Nature"},{"key":"1437_CR55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2024.11.008","volume":"36","author":"TG Chang","year":"2025","unstructured":"Chang, T. G. et al. Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer. Ann. Oncol. 36, 309\u2013320 (2025).","journal-title":"Ann. Oncol."},{"key":"1437_CR56","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1084\/jem.20021170","volume":"197","author":"CH Chen","year":"2003","unstructured":"Chen, C. H. et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med. 197, 1689\u20131699 (2003).","journal-title":"J. Exp. Med."},{"key":"1437_CR57","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853\u20131860 (2018).","journal-title":"Ann. Oncol."},{"key":"1437_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","volume":"26","author":"JE Stein","year":"2020","unstructured":"Stein, J. E. et al. Pan-tumor pathologic scoring of response to PD-(L)1 blockade. Clin. Cancer Res. 26, 545\u2013551 (2020).","journal-title":"Clin. Cancer Res"},{"key":"1437_CR59","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2024)."},{"key":"1437_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1437_CR61","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/bioinformatics\/btz698","volume":"36","author":"AS Bais","year":"2020","unstructured":"Bais, A. S. & Kostka, D. scds: computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics 36, 1150\u20131158 (2020).","journal-title":"Bioinformatics"},{"key":"1437_CR62","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1437_CR63","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"1437_CR64","doi-asserted-by":"crossref","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1\u20136 (2019).","DOI":"10.21105\/joss.01686"},{"key":"1437_CR65","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag New York, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"1437_CR66","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"1437_CR67","doi-asserted-by":"publisher","unstructured":"Taube, J. M. et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J, Immunother Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2019-000155 (2020).","DOI":"10.1136\/jitc-2019-000155"},{"key":"1437_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"1437_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","journal-title":"BMC Bioinform."},{"key":"1437_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1437_CR71","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01437-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:02:34Z","timestamp":1781827354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01437-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S.S. is an employee of ImmunityBio. E.R. is a co-founder of MedAware, Metabomed, and Pangea Biomed (divested), and an unpaid member of Pangea Biomed\u2019s and GSK Oncology scientific advisory boards. Otherwise, the authors declare that no competing interests exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}